One of the most cited concepts from is “Data Integrity by Design.” The report argues that integrity cannot be inspected into a dataset after the fact; it must be engineered into the process.
Are You Controlling Peak Integration to Ensure Data Integrity? pda technical report 80
In the pharmaceutical and biotech industries, data is not merely a byproduct of testing; it is the foundation of patient safety and product quality. Over the last decade, regulatory bodies such as the FDA, MHRA, and WHO have shifted their inspection focus from merely checking final results to scrutinizing the integrity of the data lifecycle. One of the most cited concepts from is
PDA Technical Report No. 80 provides a comprehensive framework for establishing data integrity management systems (DIMS) in pharmaceutical laboratories, focusing on risk mitigation across the data lifecycle. The guidance is noted for practical, technical insights, including specific, illustrated examples of acceptable chromatographic integration practices and recommendations for QC microbiology. More information is available on the PDA website. Chromatography Online Over the last decade, regulatory bodies such as
If you’d like, I can also summarize of TR-80 (e.g., how to implement audit trail review, or managing hybrid systems) based on known public content. Just let me know.
During an FDA or EMA inspection, mentioning that your lab is aligned with signals maturity. Conversely, failing to follow TR 80’s principles is a red flag.
PDA Technical Report 80 has had a significant impact on the pharmaceutical industry, particularly in the areas of parenteral and ophthalmic drug products. The report has provided a framework for manufacturers, testing laboratories, and regulatory agencies to ensure the sterility of these products.
